Paraneoplastic cerebellar degeneration diagnosed by anti-Yo determination in a young woman with early breast cancer

被引:0
|
作者
Mirallas, Oriol [1 ]
Rezqallah Aron, Maria Alejandra [1 ]
Saoudi Gonzalez, Nadia [1 ]
Escriva-de-Romani, Santiago [1 ]
机构
[1] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol VHIO, Med Oncol Dept, Barcelona, Catalunya, Spain
关键词
immunology; brain stem; cerebellum; movement disorders (other than Parkinsons); neurooncology; breast cancer;
D O I
10.1136/bcr-2019-233863
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A 44-year-old woman diagnosed with a HER2 positive early breast cancer, receiving neoadjuvant treatment with paclitaxel and targeted agents, trastuzumab together with pertuzumab, presented to the emergency room with gait instability and upper right limb weakness. The neurological examination was compatible with cerebellar alteration showing right dissymmetry of the finger-nose and heel-knee manoeuvre. A head CT and a brain MRI were performed and negative. The electromyography showed alterations of the pyramidal pathway and somatosensory pathway. In order to determine the cause of the cerebellar affection, a lumbar puncture was performed. The cerebrospinal fluid analysis was non-specific, but the antineuronal anti-Yo antibody was positive, being diagnosed of a paraneoplastic cerebellar degeneration (PCD). A positron emission tomography CT ruled out metastatic disease. The patient completed four cycles of antiHER2 blockade and weekly paclitaxel, achieving a complete pathological response. One year later, she maintains a complete remission but the PCD still prevails.
引用
收藏
页数:4
相关论文
共 50 条
  • [1] Anti-Yo mediated paraneoplastic cerebellar degeneration in a woman with ovarian adenocarcinoma
    Menon, S.
    Mudkanna, A.
    Unni, N.
    Singhal, B. S.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2009, 285 : S234 - S235
  • [2] PARANEOPLASTIC CEREBELLAR DEGENERATION WITH ANTI-YO ANTIBODY IN A MAN
    FELICIAN, O
    RENARD, JL
    VEGA, F
    CREANGE, A
    CHEN, QM
    BEQUET, D
    DELATTRE, JY
    NEUROLOGY, 1995, 45 (06) : 1226 - 1227
  • [3] Paraneoplastic cerebellar degeneration with anti-Yo antibodies - a review
    Venkatraman, Anand
    Opal, Puneet
    ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, 2016, 3 (08): : 655 - 663
  • [4] ACTIVATED MACROPHAGES IN PARANEOPLASTIC CEREBELLAR DEGENERATION WITH ANTI-YO ANTIBODY
    TANAKA, M
    TANAKA, K
    TSUJI, S
    NEURODEGENERATION, 1993, 2 (04): : 299 - 300
  • [5] Anti-Yo positive paraneoplastic cerebellar degeneration in the setting of cholangiocarcinoma
    Bruhnding, Aubree
    Notch, Derek
    Beard, Albertine
    JOURNAL OF CLINICAL NEUROSCIENCE, 2017, 36 : 71 - 72
  • [6] Paraneoplastic cerebellar degeneration anti-yo positive secondary to probable gynecologic cancer
    Carvalho Monteiro, G.
    Orts Castro, E.
    Hernandez Cristobal, J.
    Povedano Margarit, B.
    Yusta Izquierdo, A.
    Sanchez Heran, I.
    Celi Celi, J. M.
    EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 722 - 722
  • [7] A woman with rapidly progressive vertigo and ataxia - Paraneoplastic cerebellar degeneration due to anti-Yo antibodies
    Dalmau, Josep
    Gilberto Gonzalez, R.
    Lerwill, Melinda F.
    Batchelor
    Harris
    Schmahmann
    Ryan, David P.
    Brown, Robert H., Jr.
    NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (06): : 612 - 620
  • [8] Anti-Yo mediated paraneoplastic cerebellar degeneration in the context of breast cancer: a case report and literature review
    Key, Richard Garrett
    Root, James C.
    PSYCHO-ONCOLOGY, 2013, 22 (09) : 2152 - 2155
  • [9] Paraneoplastic Cerebellar Degeneration with Demyelinating Polyradiculoneuropathy in a Case of Anti-Yo Antibody-Positive Breast Cancer
    Mohan, Sankalp S.
    Hatekar, Khushboo S.
    Patil, Smita P.
    Shaikh, Juber D.
    NEUROLOGY INDIA, 2021, 69 (04) : 1099 - 1100
  • [10] The early diagnoses and treatment of anti-Yo antibody-mediated paraneoplastic cerebellar degeneration in a patient with breast cancer: a case report
    Wang, Wei
    Liu, Hongjin
    Liu, Yinhua
    Liu, Qian
    TRANSLATIONAL CANCER RESEARCH, 2022, : 1434 - 1439